Study Points
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
Study Points
Click on any objective to view test questions.
- Compare and contrast the mechanisms of action of commonly used anticoagulant and antiplatelet agents, including unfractionated heparin, low molecular weight heparins, vitamin K antagonists, direct thrombin inhibitors, factor Xa inhibitors, aspirin, and P2Y12 inhibitors.
- Identify best practice and evidence-based recommendations for initiating anticoagulant therapy for various conditions, including atrial fibrillation, acute coronary syndrome, prosthetic heart valves, and venous thromboembolism using risk stratification frameworks.
- Recognize clinical situations warranting antiplatelet therapy, either alone or in combination with anticoagulants, based on updated treatment guidelines for relevant vascular conditions, including acute coronary syndrome, coronary artery disease, acute ischemic stroke, and peripheral arterial disease.
- Select the most appropriate medication monitoring strategy based on specific anticoagulant or antiplatelet agent and therapeutic indication.
- Indicate safe strategies for transitioning between anticoagulant and antiplatelet agents to avoid therapy gaps or excessive overlap that can precipitate thrombotic complications or bleeding, based on indication timeframe, procedure guidance, and antithrombotic agent properties.
- Recognize special populations who may require additional monitoring of anticoagulant or antiplatelet therapies due to altered pharmacokinetics and pharmacodynamic parameters.
Which of the following medications works by inhibiting the formation of thromboxane A2 in order to achieve its antithrombotic effect?
Which of the following anticoagulants works by inhibiting the formation of factors II, VII, IX, and X as well as proteins C and S?
Which of the following is a first-line therapy for treatment of DVT in a patient with no additional comorbidities?
Which of the following is the preferred antithrombotic regimen in the management of a patient with a mechanical mitral valve?
Which of the following P2Y12 inhibitors is contraindicated in patients with a history of transient ischemic attack or stroke?
Which of the following is the most appropriate strategy to transition from a heparin infusion to dabigatran without leaving gaps in therapy?
Which of the following is the most appropriate strategy for transitioning from a cangrelor infusion to an oral P2Y12 inhibitor without leaving gaps in therapy?
Which of the following medications requires routine monitoring and titration based on antifactor Xa assay or activated partial thromboplastin time (aPTT)?
Monitoring of antifactor Xa assay for enoxaparin may be useful in which of the following special patient populations?
Which of the following is an indication for dual antiplatelet therapy (DAPT)?
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.